- Home
- IMPP vs AGEN Comparison
IMPP vs AGEN Comparison
Compare IMPP & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMPP | AGEN |
|---|---|---|
| Founded | 1981 | 1994 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.6M | 126.2M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | IMPP | AGEN |
|---|---|---|
| Price | $3.50 | $3.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.50 | ★ $14.50 |
| AVG Volume (30 Days) | 653.9K | ★ 929.6K |
| Earning Date | 02-12-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $136,071,654.00 | $106,829,000.00 |
| Revenue This Year | $7.55 | $23.68 |
| Revenue Next Year | $52.61 | $23.17 |
| P/E Ratio | $3.37 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.12 | $1.38 |
| 52 Week High | $6.57 | $7.34 |
Technical Indicators
Market Signals| Indicator | IMPP | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 36.67 | 40.27 |
| Support Level | $3.23 | $2.95 |
| Resistance Level | $3.68 | $3.55 |
| Average True Range (ATR) | 0.17 | 0.36 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 32.18 | 9.64 |
Price Performance
Historical ComparisonAbout IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).